Last reviewed 2026-04-20 · How we verify

Pf-06954522 (pf-06954522)

PF-06954522 is an investigational drug developed by Pfizer Inc. It is currently in clinical trials and has not yet received FDA approval. The drug is being evaluated for its potential in treating various conditions, but specific details about its mechanism of action, safety profile, and commercial prospects are limited due to its developmental stage. Early clinical data suggest that it may have a favorable safety profile, though more extensive studies are needed to confirm its efficacy and safety. The drug's potential market impact and competition will become clearer as it progresses through the regulatory process.

At a glance

Approved indications

• Spinal Muscular Atrophy (SMA) with a genetically confirmed diagnosis of SMA type 1, or SMA type 2 or 3 in patients with a body weight of 13 kg or less

Pipeline indications

Common side effects

No common side effects on file.

Drug interactions

• Warfarin
• P-glycoprotein inhibitors
• P-glycoprotein inducers
• CYP3A4 inhibitors
• CYP3A4 inducers

Key clinical trials

• A Study to Learn How Different Amounts of the Study Medicine Called PF-06954522 Are Tolerated and Act in the Body in Healthy Adults (PHASE1)
• A Study to Learn How Different Amounts of PF-06954522 Are Tolerated and Act in Adults With Type 2 Diabetes Mellitus (PHASE1)
• A Study to Learn How Different Forms of the Study Medicine Called PF-06954522 Are Taken up Into the Blood in Healthy Adults (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Pf-06954522 CI brief — competitive landscape report
• Pf-06954522 updates RSS · CI watch RSS
• Pfizer portfolio CI